PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21663515-0	2011	Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.	Dasatinib	28-37	solute carrier family 22 member 1	Homo sapiens	124-131	
18669873-3	2008	(14)C-dasatinib uptake was greater in KCL22-transfected cells with pcDNA3-hOCT1 plasmid (high hOCT1-expressing cells) than in control cells (P = .02).	Dasatinib	6-15	solute carrier family 22 member 1	Homo sapiens	74-79	
18669873-8	2008	Compared with imatinib, dasatinib achieved superior intracellular levels and BCR-ABL suppression even in cells with low or blocked hOCT1.	Dasatinib	24-33	solute carrier family 22 member 1	Homo sapiens	131-136	
18669873-10	2008	Dasatinib may therefore offer an advantage over imatinib in patients with low hOCT1 expression.	Dasatinib	0-9	solute carrier family 22 member 1	Homo sapiens	78-83	
18669873-3	2008	(14)C-dasatinib uptake was greater in KCL22-transfected cells with pcDNA3-hOCT1 plasmid (high hOCT1-expressing cells) than in control cells (P = .02).	Dasatinib	6-15	solute carrier family 22 member 1	Homo sapiens	94-99	
18669873-5	2008	Dasa-tinib decreased the level of phosphorylated CrkL to 49.9% in control and 40.3% in high hOCT1-expressing cells.	Dasatinib	0-10	solute carrier family 22 member 1	Homo sapiens	92-97	
18559609-3	2008	The relevance of OCT-1 activity and efflux pumps in determining intracellular uptake and retention (IUR) of dasatinib was assessed.	Dasatinib	108-117	solute carrier family 22 member 1	Homo sapiens	17-22	
18559609-8	2008	Patients with high OCT-1 activity based on their imatinib uptake had IC50(dasatinib) values equivalent to patients with low OCT-1 activity.	Dasatinib	74-83	solute carrier family 22 member 1	Homo sapiens	19-24	
25568846-0	2014	OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.	Dasatinib	95-104	solute carrier family 22 member 1	Homo sapiens	0-5	
18398725-7	2008	Uptake of the second generation tyrosine kinase inhibitors, dasatinib and nilotinib, is less dependent upon hOCT1.	Dasatinib	60-69	solute carrier family 22 member 1	Homo sapiens	108-113